Acella recalls subpotent thyroid med

May 3, 2021

Acella Pharmaceuticals has issued a voluntary recall of certain varieties of a drug used to treat underactive thyroid because routine testing found some lots contained less than the prescribed amounts of active ingredients.

The recall affects 35 lots of the drug sold as NP Thyroid in a variety of strengths, as well as three sample lots.

The drug, according to the U.S. FDA, contains less than 90 percent “of the labeled amount of liothyronine and/or levothyroxine.” The problem was discovered during routine testing.

Alpharetta, Georgia-based drugmaker has received 43 reports to date of serious adverse events that could possibly be related to the recall, the company said in a prepared statement, distributed Friday by the FDA.

Read the FDA recall alert